

0951

BSE LTD		
ACKNOWLEDGEMENT		
Acknowledgement No	: 1211202505252133	Date & Time : 12/11/2025 05:25:21 PM
Scrip Code	: 512101	
Entity Name	: Triochem Products Limited	
Compliance Type	: Regulation 33(3)-Integrated Finance Ind AS	
Quarter / Period	: 30/09/2025	
Mode	: XBRL E-Filing	

General information about company	
Scrip code*	512101
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE331E01013
Name of company	Triochem Products Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	12-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	05-11-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Second quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Unaudited
Segment Reporting	Single segment
Description of single segment	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.
Start date and time of board meeting	12-11-2025 15:00
End date and time of board meeting	12-11-2025 16:45
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	24-10-2025
Indicate Company website link for updated RPT policy of the Company	https://www.triochemproducts.com/uploads/Investor-relations/pdfs/related-party-transactions-ver04-252-4157.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	Yes

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-07-2025	01-04-2025
Date of end of reporting period		30-09-2025	30-09-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.		
1	Income		
	Revenue from operations	0	0
	Other income	29.52	51.62
	Total income	29.52	51.62
2	Expenses		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	13.76	27.28
(e)	Finance costs	0	0
(f)	Depreciation, depletion and amortisation expense	1.66	3.3
(g)	Other Expenses		
1	Other Expenses	28.71	50.89
	Total other expenses	28.71	50.89
	Total expenses	44.13	81.47
3	Total profit before exceptional items and tax	-14.61	-29.85
4	Exceptional items	0	0
5	Total profit before tax	-14.61	-29.85
6	Tax expense		
7	Current tax	0	0
8	Deferred tax	4.65	-7.53
9	Total tax expenses	4.65	-7.53
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	-19.26	-22.32
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	-19.26	-22.32
17	Other comprehensive income net of taxes	-47.02	42.25
18	Total Comprehensive Income for the period	-66.28	19.93
19	Total profit or loss, attributable to		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	Total Comprehensive income for the period attributable to		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	Details of equity share capital		
	Paid-up equity share capital	24.5	24.5
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve		
23	Earnings per share		

i	Earnings per equity share for continuing operations		
	Basic earnings (loss) per share from continuing operations	-7.86	-9.11
	Diluted earnings (loss) per share from continuing operations	-7.86	-9.11
ii	Earnings per equity share for discontinued operations		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
iii	Earnings per equity share (for continuing and discontinued operations)		
	Basic earnings (loss) per share from continuing and discontinued operations	-7.86	-9.11
	Diluted earnings (loss) per share from continuing and discontinued operations	-7.86	-9.11
24	Debt equity ratio		Textual Information(1)
25	Debt service coverage ratio		Textual Information(2)
26	Interest service coverage ratio		Textual Information(3)
27	Disclosure of notes on financial results	Textual Information(4)	

Text Block	
Textual Information(4)	1) The above unaudited standalone financial results of the Company for the quarter and half year ended 30th September 2025 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.11.2025. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon. 2) The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI). 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable. 4) The Board of Directors, at its meeting held on 24th October 2025, has approved the proposal for the sale of immovable properties, plant & machinery and investment property of the Company situated in Maharashtra. The proposed sale constitutes a Material Related Party Transaction under the provisions of Section 188 of the Companies Act, 2013 and Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the transaction shall be subject to approval of shareholders through postal ballot. The said assets proposed to be sold have an aggregate written down value (WDV) of Rs.56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounts to approximately Rs.672.05 lakhs for property, plant & machinery and Rs.509.00 lakhs for investment property. The consideration for the proposed sale shall be settled entirely in cash. Upon receipt of shareholders' approval, the said assets will be classified as 'Assets Held for Sale' in accordance with Ind AS 105 – Non-Current Assets Held for Sale and Discontinued Operations as notified under the Companies (Indian Accounting Standards) Rules, 2015. The proposed transaction is at arm's length and in the ordinary course of business, aimed at monetizing non-core assets. The proceeds from the sale are intended to be utilized for new business ventures and strategic initiatives to be undertaken by the Company. The completion of sale is expected to be concluded on or before 31st January 2026, subject to receipt of shareholders' approval. 5) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

Statement of Asset and Liabilities		
Particulars		Half Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		30-09-2025
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	50.75
	Capital work-in-progress	
	Investment property	6.18
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	1121.8
	Trade receivables, non-current	
	Loans, non-current	0
	Other non-current financial assets	9.24
	Total non-current financial assets	1131.04
	Deferred tax assets (net)	4.09
	Other non-current assets	1.01
	Total non-current assets	1193.07
2	Current assets	
	Inventories	0
	Current financial asset	
	Current investments	0
	Trade receivables, current	0
	Cash and cash equivalents	52.25
	Bank balance other than cash and cash equivalents	0
	Loans, current	0
	Other current financial assets	0.28
	Total current financial assets	52.53
	Current tax assets (net)	26.38
	Other current assets	139.41
	Total current assets	218.32
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	1411.39
	Total current assets	218.32
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	1411.39
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	24.5
	Other equity	1362.11
	Total equity attributable to owners of parent	1386.61
	Non controlling interest	
	Total equity	1386.61

2	Liabilities	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	0
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	
	Total non-current financial liabilities	0
	Provisions, non-current	0
	Deferred tax liabilities (net)	
	Deferred government grants, Non-current	
	Other non-current liabilities	
	Total non-current liabilities	0
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	0
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	16.94
	Total Trade payable	16.94
	Other current financial liabilities	0.51
	Total current financial liabilities	17.45
	Other current liabilities	
	Provisions, current	7.33
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	Total current liabilities	24.78
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	24.78
	Total equity and liabilities	1411.39
	Disclosure of notes on assets and liabilities	Textual Information(1)

Text Block	
Textual Information(1)	1) The above unaudited standalone financial results of the Company for the quarter and half year ended 30th September 2025 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 12.11.2025. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon. 2) The Unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI). 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (IND AS-108) "Segment Reporting" is not applicable. 4) The Board of Directors, at its meeting held on 24th October 2025, has approved the proposal for the sale of immovable properties, plant & machinery and investment property of the Company situated in Maharashtra. The proposed sale constitutes a Material Related Party Transaction under the provisions of Section 188 of the Companies Act, 2013 and Regulation 23 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Accordingly, the transaction shall be subject to approval of shareholders through postal ballot. The said assets proposed to be sold have an aggregate written down value (WDV) of Rs.56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounts to approximately Rs.672.05 lakhs for property, plant & machinery and Rs.509.00 lakhs for investment property. The consideration for the proposed sale shall be settled entirely in cash. Upon receipt of shareholders' approval, the said assets will be classified as 'Assets Held for Sale' in accordance with Ind AS 105 – Non-Current Assets Held for Sale and Discontinued Operations as notified under the Companies (Indian Accounting Standards) Rules, 2015. The proposed transaction is at arm's length and in the ordinary course of business, aimed at monetizing non-core assets. The proceeds from the sale are intended to be utilized for new business ventures and strategic initiatives to be undertaken by the Company. The completion of sale is expected to be concluded on or before 31st January 2026, subject to receipt of shareholders' approval. 5) The Corresponding figures of the previous quarter / year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

Other Comprehensive Income			
Date of start of reporting period		01-07-2025	01-04-2025
Date of end of reporting period		30-09-2025	30-09-2025
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Other comprehensive income [Abstract]			
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		
3	Amount of items that will be reclassified to profit and loss		
1	Items that will not be reclassified to profit or Loss	-64.87	49.28
2	Income tax relating to items that will not be reclassified to profit or loss	17.85	-7.03
	Total Amount of items that will be reclassified to profit and loss		-47.02 42.25
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income		-47.02 42.25

Cash flow statement, indirect		
Particulars		Half Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2025
Date of end of reporting period		30-09-2025
Whether results are audited or unaudited		Unaudited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	-29.85
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	0
	Adjustments for decrease (increase) in inventories	0
	Adjustments for decrease (increase) in trade receivables, current	0
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	5.67
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	0.22
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	1.44
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-0.02
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	3.3
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	-0.15
	Adjustments for provisions, current	0.95
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	8.52
	Adjustments for interest income	0.34
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0.02
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	2.57
	Net cash flows from (used in) operations	-27.28
	Dividends received	8.52
	Interest paid	0
	Interest received	0.34
	Income taxes paid (refund)	10.21
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	-28.63
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0

	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	0
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	-9.76
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	0
	Interest received	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-0.02
	Net cash flows from (used in) investing activities	-9.78
4	Cash flows from used in financing activities	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	0
	Repayments of borrowings	0
	Payments of lease liabilities	0
	Dividends paid	0
	Interest paid	0
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	0
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	-38.41
5	Effect of exchange rate changes on cash and cash equivalents	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	-38.41
	Cash and cash equivalents cash flow statement at beginning of period	90.66
	Cash and cash equivalents cash flow statement at end of period	52.25

Format for Disclosure of Related Party Transactions (applicable only for ha

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In c are part of th
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Open balan
1	Triochem Products Limited	AAACT2202J	G Amphray Laboratories (Proprietor Ramu Sitaram Deora)	AAMPD214IH	Key managerial person is proprietor	Sale of goods or services		77.88	Approved	77.88	24-05- 2025	38.94	0

[illegible]

Total value of transaction during the reporting period													38.94

14.

Format for Disclosing Outstanding Default on Loans and Debt Securities			
Sr. No.	Particulars	Amount	Remarks
1.	Loans / revolving facilities like cash credit from banks / financial institutions		
A	Total amount outstanding as on date	0	
B	Of the total amount outstanding, amount of default as on date	0	
2.	Unlisted debt securities i.e. NCDs and NCRPS		
A	Total amount outstanding as on date	0	
B	Of the total amount outstanding, amount of default as on date	0	
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	0	

Home

Validate

Format for Disclosure of Related Party Transactions (applicable only for half-yearly

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Det
	Name	PAN	Name

Add

Delete

1	Triochem Products Limited	AAACT2202J	G Amphray Laboratories (Proprietor Ramu Sitaram Deora)
---	---------------------------	------------	--

Total value of transaction during the reporting period


Notes:

Amount in (Lakhs)

filings i.e., 2nd and 4th quarter)

Details of the counterparty		Type of related party transaction	Details of other related party transaction
PAN	Relationship of the counterparty with the listed entity or its subsidiary		

AAMPD2141H	Key managerial person is proprietor	Sale of goods or services	
------------	-------------------------------------	---------------------------	--



Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved
---	--	--	---

77.88	Approved	77.88	24-05-2025
-------	----------	-------	------------



ure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate

al indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments

Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)
-------------------------------	------	--------	--

--	--	--	--

te deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be undertaken.

Details of the loans, inter-corporate deposits, advances

Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
-------------------	--------	-----------------------	--

--	--	--	--

ed to be disclosed only once, during the reporting period when such transaction was
s or investments
Notes
This is to inform you that Disclosures of the Related Party Transaction on a consolidated basis under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018 is not applicable to our Company. As per Regulation 15(2) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, the compliance with corporate governance provisions as specified in regulations 17, [17A,] 18, 19, 20, 21,22, 23, 24, 24A, 25, 26, 27 and clauses (b) to (i) [and (t)] of sub-regulation (2) of regulation 46 and para C, D and E of Schedule V shall not apply, in respect of - The listed entity having paid up equity share capital not exceeding rupees ten crore and net worth not exceeding rupees twenty-five crore, as on the last day of the previous financial year. Further, we would like to clarify that our claiming exemption under Regulation 15(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the compliance with the Corporate Governance provision shall not apply to listed entities having Paid up equity share capital not exceeding Rs.10 Crores and Net worth not exceeding Rs.25 Crores, as on last day of previous financial year. This is to certify that the paid-up equity capital of the company is Rs.24,50,000/- (Rs. Twenty-Four Lakh Fifty Thousand Only) which is less than Rs.10 Crores (Rs. Ten Crores) and Net worth is Rs.13,66,68,576/- (Rs. Thirteen Crores Sixty-Six Lakh Sixty-Eight Thousand Five Hundred Seventy-Six Only) which is less than Rs.25 Crores. (Rs. Twenty-Five Crores) as per the audited Balance sheet as at 31st March 2025, which is within the limit as prescribed in Regulation 15(2) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.